- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.02. | Syra Health secures $450K contract extension in Tennessee | 2 | Investing.com | ||
| 13.02. | Syra Health sichert sich neuen Vertrag für Schulungen im Bereich psychische Gesundheit | 2 | Investing.com Deutsch | ||
| 24.01. | Syra Health files for $75M mixed securities shelf | 1 | Seeking Alpha | ||
| 17.01. | Syra Health Corp - 8-K, Current Report | - | SEC Filings | ||
| SYRA HEALTH Aktie jetzt für 0€ handeln | |||||
| 07.01. | Why Is Syra Health Stock Surging Today? | 1 | Benzinga.com | ||
| 07.01. | Syra Health secures contracts in education, healthcare sectors | 1 | Investing.com | ||
| 07.01. | Syra Health sichert sich Verträge im Bildungs- und Gesundheitssektor | 1 | Investing.com Deutsch | ||
| 29.10.24 | Syra Health Corp - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 29.10.24 | Syra Health Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 29.10.24 | Syra Health GAAP EPS of -$0.06, revenue of $2.25M | 2 | Seeking Alpha | ||
| 29.10.24 | Syra Health Delivers Third Quarter 2024 Financial Results | 147 | PR Newswire | Achieved Net Revenue of $2.3 million, ~42% Growth Over the Prior Year Quarter
Gross Margins Increased Following Shift in Operational Strategy
Net Loss Narrowed to... ► Artikel lesen | |
| 28.10.24 | Earnings Preview: Syra Health | 2 | Benzinga.com | ||
| 21.10.24 | Syra Health faces Nasdaq delisting over share price | 1 | Investing.com | ||
| 21.10.24 | Syra Health Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 09.10.24 | Syra Health sichert sich mehrere staatliche Gesundheitsverträge | 1 | Investing.com Deutsch | ||
| 13.09.24 | Syra Health completes $2.1 million public offering | 1 | Investing.com | ||
| 13.09.24 | Syra Health schließt öffentliches Aktienangebot über 2,1 Millionen Dollar ab | - | Investing.com Deutsch | ||
| 13.09.24 | Syra Health CFO and COO Priya Prasad buys shares worth $13,256, sells for $10,143 | 1 | Investing.com | ||
| 12.09.24 | Why Syra Health Stock Is Down 50% Today | 1 | Benzinga.com | ||
| 12.09.24 | Syra Health stock dips after pricing $2.1M securities offering | 3 | Seeking Alpha |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,120 | -4,01 % | Sernova Biotherapeutics Inc: Sernova arranges $1-million debenture financing | ||
| ATOSSA THERAPEUTICS | 0,689 | -0,29 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 | SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment... ► Artikel lesen | |
| PING AN HEALTHCARE | 0,968 | -3,30 % | Ping An Healthcare and Technology Company Limited: Ping An Health Pioneers AI-Driven Healthcare with DeepSeek Integration | HONG KONG and SHANGHAI, Feb. 13, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) recently... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,019 | +8,05 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,440 | -1,79 % | Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance | The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of a test component
SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/... ► Artikel lesen | |
| CYTOSORBENTS | 0,923 | -11,93 % | Cytosorbents Corp - 8-K, Current Report | ||
| VERU | 0,491 | +1,32 % | Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress | --Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 0,747 | -1,32 % | Tempest Therapeutics: Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma | Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif.... ► Artikel lesen | |
| VOLITIONRX | 0,593 | 0,00 % | VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for
Friday, November 15 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., Nov. 14, 2024... ► Artikel lesen | |
| EKSO BIONICS | 0,412 | +1,23 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results | SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
| IMUNON | 0,820 | -0,61 % | Imunon, Inc.: IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study | IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in... ► Artikel lesen | |
| BEYOND AIR | 0,264 | 0,00 % | Beyond Air Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update | Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia; international... ► Artikel lesen | |
| AVINGER | 0,340 | -6,08 % | Avinger, Inc.: Avinger Reports Third Quarter 2024 Results | Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company... ► Artikel lesen | |
| NOVACYT | 0,580 | -1,19 % | Novacyt S.A. - Liquidity Agreement and Total Voting Rights | ||
| AROVELLA THERAPEUTICS | 0,067 | +5,51 % | AROVELLA THERAPEUTICS LIMITED: Top 20 Holders and Range of Units for Attaching Options |
Das Unternehmen SYRA HEALTH CORP kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,390 Euro und damit +5,49 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYRA HEALTH CORP finden Sie auf Wallstreet Online.
